LC–MS/MS Determination of Alectinib and its Major Human Metabolite M4 in Human Urine: Prevention of Nonspecific Binding

References

• McKeage K . Alectinib: a review of its use in advanced ALK-rearranged non-small-cell lung cancer. Drugs75 (1), 75–82 (2015).
   PubMed Web of Science ®Google Scholar
• Ou S-H I , AhnJS, De PetrisLet al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a Phase II global study. J. Clin. Oncol. 34 (7), 661–668 (2016).
   PubMed Web of Science ®Google Scholar
• Shaw A , GandhiL, GadgeelS. Phase 2 study of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer. Lancet Oncol. 17 (2), 234–242 (2016).
   PubMed Web of Science ®Google Scholar
• Gandhi L , ShawA, GadgeelS, RielyG, CetnarJ, WestHJet al. NP28761 Study Investigators. A Phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) US/Canadian population who had progressed on crizotinib (NP28761). J. Clin. Oncol. 33 (Suppl. 15), ASCO Abstract 8019 (2015).
   PubMed Web of Science ®Google Scholar
• Barlesi F , DingemansA-MC, OuIet al. Updated efficacy and safety results from a global Phase II, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). Eur. J. Cancer51 (Suppl. S3), Abstract 3101 (2015).
   Google Scholar
• Morcos PN , YuL, NieforthKet al. Absorption, distribution, metabolism, and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability/mass balance study in healthy subjects. Xenobiotica doi: 10.1080/00498254.2016.1179821 (2016) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Heinig K , MiyaK, KameiT, GueriniE, FraierDet al. Bioanalysis of alectinib and metabolite M4 in human plasma, cross-validation and impact on pharmacokinetics assessment. Bioanalysis8 (14), 1465–1479 (2016).
   PubMed Web of Science ®Google Scholar
• Li W , ZhangJ, TseFLS. Handbook of LC–MS Bioanalysis: Best Practices, Experimental Protocols, and Regulations. John Wiley & Sons, NJ, USA (2013).
   Google Scholar
• Ji AJ , JiangZ, LivsonY, DavisJA, ChuJX, WengN. Challenges in urine bioanalytical assays: overcoming nonspecific binding. Bioanalysis2 (9), 1573–1586 (2010).
   PubMed Web of Science ®Google Scholar
• Silvester S , ZhangF. Overcoming non-specific adsorption issues for AZD9164 in human urine samples: consideration of bioanalytical and metabolite identification procedures. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 893–894, 134–143 (2012).
   PubMed Web of Science ®Google Scholar
• Hilhorst M , van AmsterdamP, HeinigK, ZwanzigerE, AbbottR. Stabilization of clinical samples collected for quantitative bioanalysis – a reflection from the European Bioanalysis Forum. Bioanalysis7 (3), 333–343 (2015).
   PubMed Web of Science ®Google Scholar
• Bylda C , ThieleR, KoboldU, VolmerD. Recent advances in sample preparation techniques to overcome difficulties encountered during quantitative analysis of small molecules from biofluids using LC–MS/MS. Analyst139, 2265–2276 (2014).
   PubMed Web of Science ®Google Scholar
• Jiang H , CaoH, ZhangY, FastDM. Systematic evaluation of supported liquid extraction in reducing matrix effect and improving extraction efficiency in LC–MS/MS based bioanalysis for 10 model pharmaceutical compounds. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 891–892, 71–80 (2012).
   PubMed Web of Science ®Google Scholar
• Svanström C , HanssonGP, SvenssonLD, SennbroCJ. Development and validation of a method using supported liquid extraction for the simultaneous determination of midazolam and 1′-hydroxy-midazolam in human plasma by liquid chromatography with tandem mass spectrometry detection. J. Pharm. Biomed. Anal. 58, 71–77 (2012).
   PubMed Web of Science ®Google Scholar
• Ramesh B , ManjulaN, BijargiSR, SarmaVUM, Sita DeviP. Comparison of conventional and supported liquid extraction methods for the determination of sitagliptin and simvastatin in rat plasma by LC–ESI–MS/MS. J. Pharm. Anal. 5 (3), 161–168 (2015).
   PubMedGoogle Scholar
• Meunier C , BlondelleD, FaurePet al. Development and validation of a method using supported liquid extraction for aldosterone determination in human plasma by LC-MS/MS. Clin. Chim. Acta447, 8–15 (2015).
   PubMed Web of Science ®Google Scholar
• Gong Z , ChandlerK, WebsterS, KerleyR, BuistS, McCort-TiptonM. Simple and rapid determination of norethindrone in human plasma by supported liquid extraction and ultra performance liquid chromatography with tandem mass spectrometry. Talanta91, 77–82 (2012).
   PubMed Web of Science ®Google Scholar
• Nguyen L , ZhongWZ, PainterCL, ZhangC, RahavendranSV, ShenZ. Quantitative analysis of PD 0332991 in xenograft mouse tumor tissue by a 96-well supported liquid extraction format and liquid chromatography/mass spectrometry. J. Pharm. Biomed. Anal. 53, 228–234 (2010).
   PubMed Web of Science ®Google Scholar
• Delshanee K , CarmellaSG, PillsburyME, HechtSS. Combined analysis of N’-nitrosonornicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in the urine of cigarette smokers and e-cigarette users. J. Chromatogr. B1007, 121–126 (2015).
   PubMed Web of Science ®Google Scholar
• Domínguez-Romero JC , García-ReyesJF, Molina-DíazA. Comparative evaluation of seven different sample treatment approaches for large-scale multiclass sport drug testing in urine by liquid chromatography–mass spectrometry. J. Chromatogr. A1361, 34–42 (2014).
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research, Centre for Veterinary Medicine. Guidance for Industry: Bionanalytical Method Validation. (2001). www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf.
   Google Scholar
• Viswanathan CT , BansalS, BoothBet al. 2007 workshop/conference report – quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J. 9 (1), E30–E42 (2007).
   Web of Science ®Google Scholar
• Fast DM , KelleyM, ViswanathanCTet al. 2009 Workshop report and follow-up – AAPS workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples – implications of crystal city recommendations. AAPS J. 11 (2), 239–241 (2009).
   Google Scholar
• Kasel D , TimmermanPh. Incurred sample reanalysis: EBF’s perspective and experience. Presented at : 4th Annual Bioanalysis in Clinical Research. London, UK, 11–12 February (2009).
   Google Scholar
• Guideline on bioanalytical method validation, Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (2011). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
   Google Scholar
• Reichardt C , WeltonT. Solvents and Solvent Effects in Organic Chemistry. WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany (2011).
   Google Scholar